Boston Scientific 's ( BSX ) coronary stent portfolio was boosted with the CE Mark approval of its Synergy everolimus-eluting platinum chromium stent. The product features everolimus
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment